Exploiting polymer-based delivery systems for anti-inflammatory indirubin-based 6BIGOE derivatives in in vitro and in vivo proof-of-principle studies
test tubes containing pink fuid
Indirubin-derived 6BIGOE potently inhibits pro-inflammatory interleukin(IL)-1β and prostaglandin (PG)E2 release in human monocytes with unknown mode of action, which shall be revealed. Because of inappropriate physicochemical properties, 6BIGOE shall be encapsulated into nanoparticles based on polymers of lactic and glycolic acid, stabilized by stealth polymers and targeted with e.g. Arg-Gly-Asp (RGD) ligands. Bioactivities will be tested in primary human monocytes/macrophages and their co-cultures with endothelial cells as well as in the HET-CAV (hen’s egg test – chick area vasculosa).
Image: D. Fischer
Prof. Dr. Dagmar Fischer
Department of Chemistry and Pharmacy Division of Pharmaceutical Technology Friedrich-Alexander-Universität Erlangen-Nürnberg Cauerstr. 6 (Haus 4) 91058 Erlangen Phone: +49 9131 85-29552 email@example.com
Prof. Dr. Oliver Werz
Institute of Pharmacy (IP) Friedrich Schiller University of Jena Philosophenweg 14 07743 Jena Phone: +49 3641 9-49801 firstname.lastname@example.org